© 2000 European Society of Cardiology
The effect of valvular regurgitation on plasma Cardiotrophin-1 in patients with normal left ventricular systolic function
Department of Medicine and Therapeutics, University of Leicester Leicester, UK
* Corresponding author. Department of Medicine & Therapeutics, Robert Kilpatrick Clinical Sciences Building, Leicester Royal Infirmary, Leicester LE2 7LX, UK. Tel.: +44-116-252-3126; fax: +44-116-252-3108. E-mail address: lln1{at}le.ac.uk (L.L. Ng).
 |
Abstract |
|---|
Background: Cardiotrophin-1 (CT-1), a member of the interleukin-6 related cytokine family that act via the gp130 signalling pathway, has been shown to stimulate the assembly of sarcomeric units in series in cardiomyocytes resulting in eccentric hypertrophy, ventricular dilatation and finally loss of function. In situations of volume overload a similar form of eccentric hypertrophy occurs with time.
Aims: We hypothesised that plasma CT-1 would be raised in patients with significant mitral, tricuspid and/or aortic regurgitation (MR/TR or AR, respectively) when compared to those with no (or mild) valvular regurgitant lesion.
Methods: A novel competitive immunoluminometric assay using an in-house polyclonal antibody to amino acids 105–120 of the CT-1 sequence was developed. Seventy-eight patients (31 male, mean±S.D. age 63.5±17.9 years), all with normal left ventricular systolic function were studied. Results are expressed as mean±S.D. fmol/ml.
Results: Sixty-three subjects had no significant valvular lesion, seven had moderate/severe MR, nine had moderate/severe TR and four had moderate/severe AR. These subjects had CT-1 concentrations of 53.3±23.2, 90.5±44.4, 72.6±43.8 and 48.4±24.4, respectively (P=0.02, ANOVA). Mean log CT-1 was higher in those with moderate/severe MR when compared to those without a significant regurgitant valvular lesion (P<0.03). The only predictor of moderate/severe MR was log CT-1 (P=0.004).
Conclusion: These results suggest that plasma CT-1 is raised in those patients with moderate/severe MR in the presence of normal left ventricular systolic function. This secretion of CT-1 could potentially be the cause of ventricular dilatation and subsequent loss of contractile function in these patients. It also offers the intriguing possibility that plasma CT-1 could be used to monitor progression of mitral regurgitation biochemically.
Key Words: Heart failure • Cytokines • Valvular regurgitation • Echocardiography
Received March 20, 2000; Revised June 6, 2000; Accepted June 20, 2000
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  D. J. Hausenloy and D. M. Yellon Cardioprotective growth factors Cardiovasc Res, July 15, 2009; 83(2): 179 - 194. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Ichiki, M. Jougasaki, M. Setoguchi, J. Imamura, H. Nakashima, T. Matsuoka, M. Sonoda, K. Nakamura, S. Minagoe, and C. Tei Cardiotrophin-1 stimulates intercellular adhesion molecule-1 and monocyte chemoattractant protein-1 in human aortic endothelial cells Am J Physiol Heart Circ Physiol, February 1, 2008; 294(2): H750 - H763. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Beeri, C. Yosefy, J. L. Guerrero, F. Nesta, S. Abedat, M. Chaput, F. del Monte, M. D. Handschumacher, R. Stroud, S. Sullivan, et al. Mitral regurgitation augments post-myocardial infarction remodeling failure of hypertrophic compensation. J. Am. Coll. Cardiol., January 29, 2008; 51(4): 476 - 486. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 O. Zolk, S. Engmann, F. Munzel, and R. Krajcik Chronic cardiotrophin-1 stimulation impairs contractile function in reconstituted heart tissue Am J Physiol Endocrinol Metab, June 1, 2005; 288(6): E1214 - E1221. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. H. Freed, R. H. Cunnington, A. L. Dangerfield, J. S. Sutton, and I. M.C. Dixon Emerging evidence for the role of cardiotrophin-1 in cardiac repair in the infarcted heart Cardiovasc Res, March 1, 2005; 65(4): 782 - 792. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. H Freed, A. M Borowiec, T. Angelovska, and I. M.C Dixon Induction of protein synthesis in cardiac fibroblasts by cardiotrophin-1: integration of multiple signaling pathways Cardiovasc Res, November 1, 2003; 60(2): 365 - 375. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Wang Fill a Gab(1) in Cardiac Hypertrophy Signaling: Search a Missing Link Between gp130 and ERK5 in Hypertrophic Remodeling in Heart Circ. Res., August 8, 2003; 93(3): 186 - 188. [Full Text] [PDF]
|
|
|
|
 |
|
 O. Zolk, L. L. Ng, R. J. O'Brien, M. Weyand, and T. Eschenhagen Augmented Expression of Cardiotrophin-1 in Failing Human Hearts Is Accompanied by Diminished Glycoprotein 130 Receptor Protein Abundance Circulation, September 17, 2002; 106(12): 1442 - 1446. [Abstract] [Full Text] [PDF]
|
|